# The Efficacy and Safety Herbal Medicine for Symptom Management After HIFU Treatment in Adenomyosis: A Systematic Review and Meta-Analysis

**Authors:** Eun-Jin Kim, Young-Shin Shim, Hyun-Kyung Sung, Sang-Yeon Min

PMC · DOI: 10.3390/ph18060843 · Pharmaceuticals · 2025-06-04

## TL;DR

This study finds that herbal medicine improves symptom management after HIFU treatment for adenomyosis, with promising results on reducing lesion size and pain.

## Contribution

The study is the first to systematically review and meta-analyze the efficacy of herbal medicine as an adjunct to HIFU for adenomyosis.

## Key findings

- Herbal medicine reduced uterine and lesion volume significantly compared to HIFU alone.
- Herbal medicine improved dysmenorrhea and lowered serum estradiol and CA125 levels.
- The findings suggest herbal medicine is a safe and effective post-HIFU treatment option.

## Abstract

Background/Objectives: Adenomyosis (AM) is a hormone-dependent gynecological disorder that negatively impacts the quality of life and fertility of reproductive-age women. This study aimed to evaluate the effectiveness of herbal medicine (HM) as a post-treatment strategy following high-intensity focused ultrasound (HIFU) therapy. Methods: English, Chinese, and Korean databases were systematically searched up to 24 March 2025. Eligible randomized controlled trials (RCTs) compared HM administration after HIFU therapy with HIFU therapy alone. Statistical analyses included mean difference (MD), standardized mean difference (SMD), and risk ratio (RR) with 95% confidence intervals (CIs). Evidence quality was assessed using GRADE approach. The protocol was registered with INPLASY (No.: INPLASY202530088). Results: Fourteen RCTs involving 1259 patients were included in the review. HM administration after HIFU therapy showed superior efficacy over HIFU therapy alone in reducing uterine volume (MD = −11.84, 95% CI: −13.74 to −9.95; p < 0.00001), adenomyotic lesion volume (MD = −2.86, 95% CI: −3.29 to −2.43; p < 0.00001), serum CA125 levels (SMD = −1.49, 95% CI: −2.41 to −0.58; p < 0.00001), serum estradiol (E2) levels (SMD = −1.28, 95% CI: −1.54 to −1.03; p < 0.0001), and improvements in dysmenorrhea (MD = −0.54, 95% CI: −1.06 to −0.02; p < 0.00001) Conclusions: HM may be an effective and safe adjunct to HIFU for managing AM. However, further high-quality RCTs with long-term follow-up are needed to validate these findings.

## Linked entities

- **Diseases:** adenomyosis (MONDO:0010888)

## Full-text entities

- **Genes:** MUC16 (mucin 16, cell surface associated) [NCBI Gene 94025] {aka CA125}
- **Diseases:** AM (MESH:D062788), gynecological disorder (MESH:D005831), dysmenorrhea (MESH:D004412), adenomyotic lesion (MESH:D009059)
- **Chemicals:** E2 (MESH:D004958)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12195669/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12195669/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12195669/full.md

---
Source: https://tomesphere.com/paper/PMC12195669